Correction: Replication Study: BET bromodomain inhibition as a therapeutic strategy to target c-Myc

Correction: Replication Study: BET bromodomain inhibition as a therapeutic strategy to target c-Myc

Bibliographic Details
Main Authors:	Fraser Aird, Irawati Kandela, Christine Mantis, Reproducibility Project: Cancer Biology
Format:	Article
Language:	English
Published:	eLife Sciences Publications Ltd 2018-01-01
Series:	eLife
Online Access:	https://elifesciences.org/articles/34572

Similar Items

Replication Study: BET bromodomain inhibition as a therapeutic strategy to target c-Myc
by: Fraser Aird, et al.
Published: (2017-01-01)

Registered report: BET bromodomain inhibition as a therapeutic strategy to target c-Myc
by: Irawati Kandela, et al.
Published: (2015-06-01)

Replication Study: Coadministration of a tumor-penetrating peptide enhances the efficacy of cancer drugs
by: Christine Mantis, et al.
Published: (2017-01-01)

Replication Study: Discovery and preclinical validation of drug indications using compendia of public gene expression data
by: Irawati Kandela, et al.
Published: (2017-01-01)

BET Bromodomain Inhibition as a Therapeutic Strategy to Target c-Myc
by: Delmore, Jake E, et al.
Published: (2014)

Correction: Replication Study: Inhibition of BET recruitment to chromatin as an effective treatment for MLL-fusion leukaemia
by: Xiaochuan Shan, et al.
Published: (2018-01-01)

Replication Study: Inhibition of BET recruitment to chromatin as an effective treatment for MLL-fusion leukaemia
by: Xiaochuan Shan, et al.
Published: (2017-06-01)

Selective BET bromodomain inhibition as an antifungal therapeutic strategy
by: Flore Mietton, et al.
Published: (2017-05-01)

Correction: Registered report: Coadministration of a tumor-penetrating peptide enhances the efficacy of cancer drugs
by: Irawati Kandela, et al.
Published: (2015-06-01)

Registered report: Discovery and preclinical validation of drug indications using compendia of public gene expression data
by: Irawati Kandela, et al.
Published: (2015-05-01)

Neuronal differentiation and cell-cycle programs mediate response to BET-bromodomain inhibition in MYC-driven medulloblastoma
by: Pratiti Bandopadhayay, et al.
Published: (2019-06-01)

Neuronal differentiation and cell-cycle programs mediate response to BET-bromodomain inhibition in MYC-driven medulloblastoma
by: Bandopadhayay, Pratiti, et al.
Published: (2020)

Replication Study: The CD47-signal regulatory protein alpha (SIRPa) interaction is a therapeutic target for human solid tumors
by: Stephen K Horrigan, et al.
Published: (2017-01-01)

Registered report: Coadministration of a tumor-penetrating peptide enhances the efficacy of cancer drugs
by: Irawati Kandela, et al.
Published: (2015-05-01)

Immunogenicity of prostate cancer is augmented by BET bromodomain inhibition
by: Wendy Mao, et al.
Published: (2019-10-01)

Replication Study: Fusobacterium nucleatum infection is prevalent in human colorectal carcinoma
by: John Repass, et al.
Published: (2018-03-01)

Bromodomain Inhibitors as Therapeutics for Herpesvirus-Related Disease: All BETs Are Off?
by: Ian J. Groves, et al.
Published: (2020-07-01)

BET Bromodomain Inhibition Synergizes with PARP Inhibitor in Epithelial Ovarian Cancer
by: Sergey Karakashev, et al.
Published: (2017-12-01)

Replication Study: Transcriptional amplification in tumor cells with elevated c-Myc
by: L Michelle Lewis, et al.
Published: (2018-01-01)

Targeting Hippo coactivator YAP1 through BET bromodomain inhibition in esophageal adenocarcinoma
by: Shumei Song, et al.
Published: (2020-06-01)

Registered report: Inhibition of BET recruitment to chromatin as an effective treatment for MLL-fusion leukemia
by: Juan José Fung, et al.
Published: (2015-09-01)

Registered report: Transcriptional amplification in tumor cells with elevated c-Myc
by: David Blum, et al.
Published: (2015-01-01)

Bromodomain and Extraterminal (BET) Protein Inhibition Restores Redox Balance and Inhibits Myofibroblast Activation
by: Carmel J. W. Stock, et al.
Published: (2019-01-01)

BET bromodomain inhibition promotes neurogenesis while inhibiting gliogenesis in neural progenitor cells
by: Jingjun Li, et al.
Published: (2016-09-01)

Replication Study: Intestinal inflammation targets cancer-inducing activity of the microbiota
by: Kathryn Eaton, et al.
Published: (2018-10-01)

A 'bump-&-hole' approach for engineering allele-selective inhibition of the BET bromodomains
by: Runcie, Andrew C.
Published: (2019)

Replication Study: A coding-independent function of gene and pseudogene mRNAs regulates tumour biology
by: John Kerwin, et al.
Published: (2020-04-01)

Bromodomain Blockade for Intimal Hyperplasia — A Good BET?
by: Allison C. Ostriker, et al.
Published: (2015-11-01)

Triazolobenzodiazepines and -triazepines as protein interaction inhibitors targeting bromodomains of the BET family
by: Wrobel, Matthias
Published: (2014)

The Bromodomain and Extra-Terminal Domain (BET) Family: Functional Anatomy of BET Paralogous Proteins
by: Yasushi Taniguchi
Published: (2016-11-01)

BET Bromodomain Inhibition Releases the Mediator Complex from Select cis-Regulatory Elements
by: Anand S. Bhagwat, et al.
Published: (2016-04-01)

Dietary Compound Resveratrol Is a Pan-BET Bromodomain Inhibitor
by: Luiz Antonio Dutra, et al.
Published: (2017-10-01)

BET bromodomain proteins regulate enhancer function during adipogenesis
by: Brown, Jonathan D., et al.
Published: (2018)

Reprogramming by De-bookmarking the Somatic Transcriptional Program through Targeting of BET Bromodomains
by: Zhicheng Shao, et al.
Published: (2016-09-01)

BET Bromodomain Inhibition Promotes Anti-tumor Immunity by Suppressing PD-L1 Expression
by: Hengrui Zhu, et al.
Published: (2016-09-01)

Inhibition of Lapatinib-Induced Kinome Reprogramming in ERBB2-Positive Breast Cancer by Targeting BET Family Bromodomains
by: Timothy J. Stuhlmiller, et al.
Published: (2015-04-01)

Targeting bromodomain-containing protein 4 (BRD4) inhibits MYC expression in colorectal cancer cells
by: C. Otto, et al.
Published: (2019-11-01)

Resistance to BET Bromodomain Inhibitors Is Mediated by Kinome Reprogramming in Ovarian Cancer
by: Alison M. Kurimchak, et al.
Published: (2016-08-01)

Bromodomain and extra-terminal domain (BET) proteins regulate melanocyte differentiation
by: Archit Trivedi, et al.
Published: (2020-03-01)

Effect of BET Missense Mutations on Bromodomain Function, Inhibitor Binding and Stability.
by: Laura Lori, et al.
Published: (2016-01-01)